The Tempus Homologous Recombination Deficiency (HRD) test is a DNA-based test, available as part of the xT platform, for clinicians aiming to better understand if their patient has Homologous Recombination Deficiency. Tempus HRD is a comprehensive view into a patient’s ability to repair double-stranded DNA breaks. HRD status can be used to identify patients who may be sensitive to PARP inhibitors and/or platinum-based chemotherapy.
The Tempus HRD test takes into account results from our xT Sequencing Panel, giving a full view into 18 commonly mutated genes in the HR-pathway, along with a genome wide loss-of-heterozygosity (LOH) score, giving a clinician one of the most complete views of HRD status on the market. The HRD test can be ordered with 6 major cancer subtypes: Ovarian, Breast, Pancreatic, Prostate, Non-small-cell lung cancer, and Glioblastoma, and does not require additional tissue from the patient.
The Tempus HRD advantages:
Tempus|TO is an RNA-based next-generation sequencing (NGS) test that predicts the diagnosis of cancers of unknown primary (CUPs) to provide guidance for physicians in cases where imaging and immunohistochemistry stains have ambiguous evidence about the origin of the tumor. The Tempus|TO test compares a patient’s tumor molecular data to a large internal database of annotated tumor data. Identifying a diagnosis impacts standard of care therapy decisions, clinical trial enrollment, and reimbursement for therapies.
The test is currently in development. To learn more about the Tempus|TO test, please email email@example.com.